GlassScriptPhysician profile
Marc S Gottlieb
NPI 1306898325
$4,461.87
in general payments reported to CMS, 2019-2025
34 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $867 · 2021: $1,264 · 2022: $493 · 2023: $32.56 · 2024: $87.36 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $783.27 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $634.07 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.00 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $504.70 | 2019-2024 | Opsumit |
| Grifols USA, LLC | $297.36 | 2019-2022 | |
| Electromed, INC. | $225.72 | 2019-2022 | |
| Philips North America LLC | $135.68 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $130.56 | 2019 | |
| Genzyme Corporation | $112.30 | 2019-2021 | |
| Mylan Specialty L.P. | $107.21 | 2019-2021 | |
| Angiodynamics, INC. | $102.56 | 2025 | Auryon Laser System 100-120 Vac |
| Sunovion Pharmaceuticals INC. | $89.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.10 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $77.68 | 2021 | |
| Harmony Biosciences LLC | $76.58 | 2020-2023 | Wakix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.31 | 2022-2025 | Zerbaxa |
| Genentech USA, INC. | $57.65 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $52.48 | 2019-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $46.10 | 2020 | |
| Gilead Sciences, INC. | $39.29 | 2019 | |
| United Therapeutics Corporation | $34.73 | 2021-2022 | |
| Circassia INC. | $25.06 | 2019 | |
| Viatris Specialty LLC | $21.60 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $21.58 | 2019 | |
| Vifor Pharma, INC. | $19.41 | 2024 | Zemaira |
| Insmed, INC. | $17.84 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.75 | 2019 | |
| Axsome Therapeutics, INC. | $17.65 | 2025 | Sunosi |
| Paratek Pharmaceuticals, INC. | $17.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.02 | 2021 | |
| Pfizer INC. | $16.52 | 2022 | |
| Olympus America INC. | $15.28 | 2021 | |
| Novo Nordisk INC | $15.11 | 2023 | Ozempic, Rybelsus |
| Inogen, INC. | $5.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.